New Hope in Depression Research - PsyRx Reports Promising Findings from an Ibogaine Study
The study, conducted in 105 mice, examined the effects of ibogaine, citalopram and their combination on behavioral measures associated with depression and anxiety TEL AVIV, Israel, Oct. 21, 2026 /PRNewswire/ -- PsyRx (TASE: PSRX) reports that it has received results from a preclinical...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


